SATISFYER_1170x120_8-13-20

Biofourmis

Biofourmis expands into oncology market with acquisition of Gaido Health

Biofourmis expands into oncology market with acquisition of Gaido Health

BOSTON – Biofourmis, a global leader in digital therapeutics that powers personalized predictive care, announced today it has finalized an agreement to acquire Gaido Health from Takeda Pharmaceuticals, a strategic deal that expands Biofourmis’ portfolio in the oncology space. Gaido Health—a Los Angeles-area based digital therapeutics company focused on the oncology market—was part of Takeda

Biofourmis announces acquisition of Biovotion AG

Biofourmis announces acquisition of Biovotion AG

BOSTON – Biofourmis has reached an agreement to acquire Zürich, Switzerland-based Biovotion AG, a leading developer of a cutting-edge clinical-grade wearable biosensor platform. The acquisition includes all of Biovotion’s assets, including the market-leading Everion biosensor and more than 60 global patents covering most of the wearable and sensor technology that exists for the arm or

Biofourmis forms alliance with Novartis

Biofourmis forms alliance with Novartis

BOSTON – Biofourmis announced Monday it has been selected by Novartis, a global healthcare company, to collaborate on a commercial project for managing patients with heart failure (HF) beginning in Southeast Asia, with potential plans to expand globally. The goal of the program is to improve clinical outcomes by using Biofourmis’ lead product BiovitalsHF, which